COMPANY NEWS

We received a patent!
Dear friends,

We are glad to announce that on February 11, 2019, we were granted a patent for the "Method of unmarked single-molecule DNA sequencing and the device for its implementation"!

In the patent the way and the device of determination of the nucleotide sequence of a molecule of nucleinic acid is offered.
Follow our news on the website and on FB.

2018 Results

Dear friends!
We are happy to congratulate you on the New Year 2019 and wish you success!
2018 results in short:

 

JANUARY:
The expertise of the project in the Skolkovo Foundation  (application for a non-dilutive financing) was completed positively.


We received a certificate of the computer program state registration №2018611229 called “The program of logic-mathematical 3D modeling of DNA polymerization reaction”.

FEBRUARY:

The Grant Committee of the Skolkovo Foundation approved a non-dilutive financing of “GAMMA-DNA LLC” according to the results of the expertise and a pitch of the project.



MARCH:

An application for an international patent for an invention (PCT) called “Method of Single-molecule Label-free DNA Sequencing and device for its realization” was filed.


APRIL-MAY:

There was an active interaction with investors (business angels and funds) and partners (Zethea, Moscow state University, NauTech, TFK Skolkovo, Skolkovo IP center), discussion of investment conditions and conditions of cooperation with partners.

JUNE:

Deal structuring with business angels, closing of the pre-seed round first stage.

Four business angels joined our project. They enriched the project with competencies in the field of artificial intelligence, nanotechnology and finance.

JULY:

The development within the pre-seed round was started according to the plan. We’ve purchased the equipment and prepared the laboratory; agreed technical specifications for polymerase and sensors with partners; concluded the agreements with partners.

We’ve also developed all technical requirements and methods, experimental design documentation for sensors, the microfluidic device, as well as for measuring stand and a layout of the key nodes of the DNA sequencer.

We took part in the industry-specific event – 2nd international conference "Bioinformatics: from algorithms to application" in St. Petersburg.

AUGUST:

We have opened a laboratory, staffed a team by biochemists, engineers, specialists in the field of information technology. Our mentors are actively involved in the work.

The preparation of technical requirements for the design of a prototype sensor cell matrix using standard TSMC technology was started.

SEPTEMBER:

Technological, business and legal expertise of the project by G&S I Fund LP (USA) for the further possible investment of the 2nd stage of the pre-seed round was carried out.

The development of the physical and mathematical model of the signal formation for sensors.

OCTOBER:

G&S I Fund LP (USA) took a positive decision to participate in the project and invest GAMMA-DNA LLC.

Charles Edward Shearer, General Partner, G&S I Fund LP (USA):

We have long been interested in the breakthrough venture projects in the field of medicine with a rich technological basis and high potential for commercial success. We were happy to make a positive decision about investing in the high-tech project, presented by GAMMA-DNA LLC. Our decision was based on the results of the deep due diligence, as well as the communication with the project team. We assessed the risks as acceptable for us at the pre-seed stage both due to the technological perspective of the project and its feasibility and due to the experience and professionalism of the project team: each of the technological directions and the direction of the business development are headed by experts with the deep knowledge and practical experience in their professional fields.

The uniqueness of the technology and its strategic potential to competitors are impressive. We intend to assist GAMMA-DNA LLC in building commercial and partnership relations and entering the markets of Asia and the USA, including licensing and promotion.

Nadya V. Matveyeva, Head of Business Development and Investor Relations, GAMMA-DNA LLC:

G&S I Fund LP is an important strategic partner for us – both in assisting in entering foreign markets and in the attraction of foreign investment for the subsequent rounds. The US market is monopolized by the leader (Illumina) and initially was not in the list of our strategical potential foreign markets. But with the assistance of the G&S I Fund LP team, the issue of representation in the US may well be considered.

Our key task today is to ensure for all the shareholders of the company the optimal balance between the volume of new investments attracted and the speed of R&D and business development in order to reduce the time to market.

Also, in October we’ve developed technological regulations for the manufacturing of two types of sensors and we’ve developed the analog-to-digital circuit and signal processing topology for charge-sensitive matrix cell in accordance to TSMC technology in October.

Participation in the 7th Moscow International Forum «Open Innovations» at the SKOLKOVO innovation center. In the competition of projects "We are from NTI" project "GAMMA-DNA" took 1st place in HealthNet unanimously! Find more details – here.

NOVEMBER:

The first batch of polymerase that was manufactured by Zethea according to the technical specifications of GAMMA-DNA was received. The polymerase corresponds to the planned characteristics.

We received prototypes of two variants of the sensor manufactured by MSU according to the technical specifications of GAMMA-DNA. Sensors parameters correspond to the planned.

The development of software to control the layout blocks of the key nodes of the DNA sequencer was started. Also, we’ve started started the development of software for the formation and demonstration of the DNA fragment sequencing results by the layout of the key nodes of the DNA sequencer.

 

DECEMBER:

The measuring stand was manufactured and tested. It is designed to test for the serviceability of two variants of sensors and for measuring their electrical parameters. The measuring stand is necessary to select the best sensor from two variants of sensors for use it in subsequent experiments with biological material.

We’ve also developed the concept of experiments to demonstrate the results of the ordered oligonucleotide sequencing. The oligonucleotide is already been bought and is stored in the freezer.

The know-how of the method of DNA samples preparation for use in a single-molecule DNA sequencing was registered. Also we’ve registered the know-how of the unique algorithm of a single-molecule DNA sequencing.

Michael Gutorov, CEO, Head of Physics and Electronics, GAMMA-DNA LLC

From the point of our R&D, 2018 made it possible to make a significant progress in the work and to make closer the day of the demonstration of a sequence of the ordered oligonucleotide on the layout of the key nodes of our DNA sequencer (prototype).

Planned R&D and business development tasks were completed. The patent application for international status (PCT) for the invention “Method of Single-molecule Label-free DNA Sequencing and device for its realization” was filed ahead of a schedule.

Each department leader has formed a team of specialists who have successfully passed the trial period. Today, the staff of employees is 17, also our scientific consultant and 2 mentors work with us.

The laboratory is equipped with all the necessary equipment.

With such results and resources, we’ve confidently stepped into 2019!

Follow our news on the website and on FB.

GAMMA-DNA LLC won the 1st place in HealthNet at Open Innovations 2018!

 
19.10.2018

The 15-17th of October 2018 there was the 7th Moscow International Forum «Open Innovations» at the SKOLKOVO innovation center. Organizer of the forum is The National Technological Initiative (NTI) - state program for creation of fundamentally new markets and the creation of conditions for global technological leadership of Russia.
 
GAMMA-DNA LLC team took an active part in the forum session " We are from NTI".
Nadya V. Matveyeva, Head of business development and investor relations, opened the session with the presentation of our single-molecule DNA sequencer project. The presentation was for potential investors, representatives of corporations and NTI regions.
Mikhail Gutorov, CEO and Head of R&D of GAMMA-DNA LLC, took part in the discussion of the project.
 
In the competition of projects "We are from NTI" project "GAMMA-DNA" took 1st place in HealthNet unanimously!

That's how it was:

at the entrance

at the exit

 
 
Follow our news on the website and on FB.

Polymerase development: we’ve started - in partnership with ZETHEA

 
26.07.2018

On 20.07.2018, our new partner – ZETHEA INC. (USA, Silicon Valley) – has started to develop a specially modified polymerase. Polymerase is an enzyme necessary for carrying out the polymerization reaction –an important part in the process of sequencing (decoding) the DNA molecule. The quality of modification affects the result of sequencing, its timing and (in conjunction with our sensors described in the news 13.07.2018) the accuracy of the result.

Polymerase is developed in ZETHEA laboratory according to our Work Specification. In the coming year, we get three batches of enzyme for testing. A sample will be selected that works most efficiently in the process of demonstration of sequence of the ordered oligonucleotide.

In the next stage (in a year), the efficiency of the experimental and prototype polymerase will be checked by the achievement of the planned rate of the polymerization reaction, including on the TSMC matrices of the sensor cells (see news from 13.07.2018) – this rate will allow sequencing of full genome for 4 hours, with an accuracy 99,9999%.

We will also obtain methods for the production of the selected enzyme with the best efficiency. Thus, we will be able to manufacture polymerase in our laboratory in the quantities required for testing, or go on with production partnership with ZETHEA.

Follow our news on the website and on FB.

MAJOR CONTRACTS APPROVED

 
13.07.2018

Two major contracts were finally approved and signed at the beginning of this week. These contracts contribute to the project technological goals achievement for this year and form the basis for the Sequencer industrial sample development.

Our new partners – MSU and NAUTECH LLC – will carry out works and consultations in accordance with Works Specification by GAMMA-DNA:
1)    Manufacturing of two types of nanoscale transistors (sensors) for polymerase immobilization (MSU),
2)    Adaptation of transistors for industrial technologies (NAUTECH LLC).

Our team will choose from two types of transistors the best one with the highest sensitivity to the results of immobilized polymerase work as well as compliance with the TSMC, industrial technologies, where we are planning to manufacture shuttles for future production of ultra-cheap sequencer matrices of GAMMA-DNA LLC. Thus, we initially minimize the design time of sensor cell matrix chips and hedge the technological risks of industrial launch.

At this stage (in 353 days), the sequence of the ordered oligonucleotide (DNA fragment) will be demonstrated on the selected sensor installed on the layout of the DNA sequencer key nodes.

Follow us on FB.










Nanoscale transistor in the chip. The photos were taken during the experimental work.